Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Summary Driver mutations in oncogenes encode proteins with gain-of-function properties that enhance fitness. Heterozygous mutations are thus viewed as sufficient for tumorigenesis. We describe widespread oncogenic mutant allele imbalance in 13,448 prospectively characterized cancers. Imbalance was selected for through modest dosage increases of gain-of-fitness mutations. Negative selection targeted haplo-essential effectors of the spliceosome. Loss of the normal allele comprised a distinct class of imbalance driven by competitive fitness, which correlated with enhanced response to targeted therapies. In many cancers, an antecedent oncogenic mutation drove evolutionarily dependent allele-specific imbalance. In other instances, oncogenic mutations co-opted independent copy number changes via the evolutionary process of exaptation. Oncogenic allele imbalance is a pervasive evolutionary innovation that enhances fitness and modulates sensitivity to targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Self-citationExaptation—a missing term in the science of form
Gould, S. J., & Vrba, E. S. (1982) · Paleobiology · doi:10.1017/s0094837300004310 · Cited by 5,136 · cited 2×
“Although the exact reason for the evolution of feathers is unknown (hypotheses include temperature regulation), they were only later adopted for flight (Gould and Vrba, 1982).”
BackgroundZehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 2×
“To study the landscape of selection for oncogenic mutant allele imbalance, we applied these approaches to 1,229 unique driver mutations and 17,352 likely passenger mutations across 69 oncogenes in a prospectively sequenced cohort of 13,448 advanced solid cancers from 53 cancer types (Tables S1 and S2) (Zehir et al., 2…”
MethodSelf-citationDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · cited 1×
“To ensure our classification of driver and passenger (or VUS) mutations in oncogenes did not inadvertently misclassify true driver mutations as VUSs, as would be predicted by recent saturation analyses of driver mutations in cancer (Chang et al., 2018; Lawrence et al., 2014), we expressed nine MAP2K1 (MEK1) variants o…”
BackgroundMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119 · cited 2×
“Briefly, matched tumor and normal specimens were sequenced (to 500-1000-fold sequence coverage) with a validated capture-based next-generation sequencing assay called MSKIMPACT that is New York state-approved for clinical use (Cheng et al., 2015).”
MethodSelf-citationFrequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029 · cited 1×
“To test this hypothesis, we assessed tumors harboring hotspot mutations in genes that encode obligatory members of the human spliceosome (Graubert et al., 2012; Papaemmanuil et al., 2011; Yoshida et al., 2011) including SF3B1 (K700, R625, E902, K666, V701), U2AF1 (S34 and 124), and SRSF2 (P95).”
BackgroundUniversal Patterns of Selection in Cancer and Somatic Tissues
Martincorena, I., Raine, K. M., Gerstung, M., Dawson, K. J., Haase, K., Van Loo, P., Davies, H., Stratton, M. R., & Campbell, P. J. (2017) · Cell · doi:10.1016/j.cell.2017.09.042 · Cited by 1,523
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222 · cited 1×
“To test this hypothesis, we assessed tumors harboring hotspot mutations in genes that encode obligatory members of the human spliceosome (Graubert et al., 2012; Papaemmanuil et al., 2011; Yoshida et al., 2011) including SF3B1 (K700, R625, E902, K666, V701), U2AF1 (S34 and 124), and SRSF2 (P95).”
BackgroundChang, M. T., Asthana, S., Gao, S. P., Lee, B. H., Chapman, J. S., Kandoth, C., Gao, J., Socci, N. D., Solit, D. B., Olshen, A. B., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3391 · Cited by 808
Self-citationClonal status of actionable driver events and the timing of mutational processes in cancer evolution
McGranahan, N., Favero, F., de Bruin, E. C., Birkbak, N. J., Szallasi, Z., & Swanton, C. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1408 · Cited by 685 · cited 1×
“Cancer cell fractions (CCF) were calculated using a binomial distribution and maximum likelihood (ML) estimation, normalized to produce posterior probabilities (McGranahan et al., 2015).”
MethodEffect of read-mapping biases on detecting allele-specific expression from RNA-sequencing data.
Degner, J. F., Marioni, J. C., Pai, A. A., Pickrell, J. K., Nkadori, E., Gilad, Y., & Pritchard, J. K. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp579 · Cited by 502 · cited 1×
“2A) likely due to the effect of reference bias (Degner et al., 2009).”
BackgroundKRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Ambrogio, C., Köhler, J., Zhou, Z.-W., Wang, H., Paranal, R., Li, J., Capelletti, M., Caffarra, C., Li, S., Lv, Q., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.020 · Cited by 270 · cited 1×
“In cultured cell lines and animal models, the functional implications of subtle changes in the allelic copy number of specific mutant oncogenes have been explored to some extent, particularly the biologic role of WT Ras alleles in heterozygous Ras-mutant tumors (Ambrogio et al., 2018; Bentley et al., 2013; Bremner and…”
BackgroundSynthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations
Lee, S. C.-W., North, K., Kim, E., Jang, E., Obeng, E., Lu, S. X., Liu, B., Inoue, D., Yoshimi, A., Ki, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.003 · Cited by 219 · cited 1×
“Genetically engineered mouse models of these mutations have shown that neither hemizygous (mutant/null) nor homozygous (mutant/mutant) states are tolerated (Fei et al., 2016; Lee et al., 2018; Zhou et al., 2015).”
BackgroundKRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer
Burgess, M. R., Hwang, E., Mroue, R., Bielski, C. M., Wandler, A. M., Huang, B. J., Firestone, A. J., Young, A., Lacap, J. A., Crocker, L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.01.020 · Cited by 183 · cited 8×
“The X for CN-LOH reflects linkage between two chromosomes, as in the case of uniparental disomy.”
BackgroundResultInfluentialSelf-citation
Cited by
PI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
Big data in basic and translational cancer research
Jiang, P., Sinha, S., Aldape, K., Hannenhalli, S., Sahinalp, C., & Ruppin, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00502-0 · Cited by 254
“Variant interpretation in clinical decisions is still challenging as the oncogenic impact of each mutation depends on its clonality 83 , zygosity 84 and co-occurrences with other mutations 85 .”
BackgroundToward a More Precise Future for Oncology
Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.014 · Cited by 48
Self-citationThe role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42
“KRAS MASI is associated with worse prognosis in colorectal cancer and pancreatic cancer [44] and loss of the WT KRAS allele has been found at a higher rate in metastatic KRAS-mutated lung and pancreatic cancers compared to the primary tumors [36,37].”
Background
Metadata
- Authors
- Bielski, C. M., Donoghue, M. T. A., Gadiya, M., Hanrahan, A. J., Won, H. H., Chang, M. T., Jonsson, P., Penson, A. V., Gorelick, A., Harris, C., Schram, A. M., Syed, A., Zehir, A., Chapman, P. B., Hyman, D. M., Solit, D. B., Shannon, K., Chandarlapaty, S., Berger, M. F., & Taylor, B. S.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 34
- Issue
- 5
- Pages
- 852-862.e4
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2899409885
- Cited by
- 106
- References
- 16
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.